tradingkey.logo

Neurocrine Biosciences Inc

NBIX

127.440USD

-1.470-1.14%
交易中 美東報價延遲15分鐘
12.62B總市值
41.26本益比TTM

Neurocrine Biosciences Inc

127.440

-1.470-1.14%
關於 Neurocrine Biosciences Inc 公司
Neurocrine Biosciences, Inc. 是一家專注於神經科學的生物製藥公司。該公司致力於發現和開發治療神經、神經內分泌和神經精神疾病的藥物,這些疾病尚未得到充分治療。其多元化的產品組合包括美國食品藥品管理局批准的治療遲發性運動障礙、與亨廷頓氏病相關的舞蹈症、子宮內膜異位症和子宮肌瘤的藥物,以及強大的產品線,包括多個處於中後期臨牀開發階段的化合物,涉及其核心治療領域。其商業產品包括 INGREZZA、ALKINDI、EFMODY、Orilissa 和 Oriahnn。INGREZZA 在日本以 DYSVAL(伐貝那嗪)的名稱銷售,在其他特定亞洲市場以 REMLEAS(伐貝那嗪)的名稱銷售,三菱田邊製藥株式會社保留這些市場的商業化權利。 ALKINDI 在美國以 ALKINDI SPRINKLE(氫化可的松)的名稱銷售,Eton Pharmaceuticals, Inc. 保留其商業化權利。
公司簡介
公司代碼NBIX
公司名稱Neurocrine Biosciences Inc
上市日期May 23, 1996
CEODr. Kyle W. Gano, Ph.D.
員工數量1800
證券類型Ordinary Share
年結日May 23
公司地址6027 Edgewood Bend Court
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92130
電話18586177600
網址https://www.neurocrine.com/
公司代碼NBIX
上市日期May 23, 1996
CEODr. Kyle W. Gano, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kyle W. Gano, Ph.D.
Dr. Kyle W. Gano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.11K
+0.14%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Director
Independent Director
120.48K
+1.21%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
40.36K
+7.65%
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Independent Director
Independent Director
34.48K
+9.08%
Mr. Darin M. Lippoldt, J.D.
Mr. Darin M. Lippoldt, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.10K
+8.90%
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.29K
--
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
13.54K
+26.88%
Mr. George J. Morrow
Mr. George J. Morrow
Independent Director
Independent Director
7.07K
+68.33%
Ms. Johanna Mercier
Ms. Johanna Mercier
Independent Director
Independent Director
3.54K
+68.33%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Kyle W. Gano, Ph.D.
Dr. Kyle W. Gano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.11K
+0.14%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Director
Independent Director
120.48K
+1.21%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
40.36K
+7.65%
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Independent Director
Independent Director
34.48K
+9.08%
Mr. Darin M. Lippoldt, J.D.
Mr. Darin M. Lippoldt, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.10K
+8.90%
收入明細
FY2024
FY2023
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
INGREZZA
2.31B
0.00%
Other
17.10M
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
INGREZZA
2.31B
0.00%
Other
17.10M
0.00%
股東統計
更新時間: 5月15日 週四
更新時間: 5月15日 週四
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
10.87%
The Vanguard Group, Inc.
9.98%
Dodge & Cox
5.58%
State Street Global Advisors (US)
4.90%
Renaissance Technologies LLC
2.52%
Other
66.15%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
10.87%
The Vanguard Group, Inc.
9.98%
Dodge & Cox
5.58%
State Street Global Advisors (US)
4.90%
Renaissance Technologies LLC
2.52%
Other
66.15%
股東類型
持股股東
佔比
Investment Advisor
44.97%
Investment Advisor/Hedge Fund
33.61%
Hedge Fund
11.66%
Pension Fund
2.53%
Research Firm
2.09%
Bank and Trust
1.46%
Individual Investor
1.06%
Private Equity
1.05%
Family Office
0.56%
Other
1.01%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
1305
98.03M
98.85%
-6.73M
2025Q1
1337
99.69M
100.72%
-4.46M
2024Q4
1312
98.79M
98.90%
-3.53M
2024Q3
1263
97.40M
96.49%
-4.44M
2024Q2
1241
97.92M
97.33%
-1.65M
2024Q1
1200
97.20M
96.69%
-3.28M
2023Q4
1158
96.37M
98.09%
-3.68M
2023Q3
1123
95.61M
97.90%
-5.53M
2023Q2
1101
95.03M
97.40%
-6.72M
2023Q1
1121
95.04M
97.47%
-5.05M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
10.78M
10.89%
-179.10K
-1.63%
Mar 31, 2025
The Vanguard Group, Inc.
9.90M
10%
-228.88K
-2.26%
Mar 31, 2025
Dodge & Cox
5.53M
5.59%
+2.52M
+83.48%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
4.91%
-29.02K
-0.59%
Mar 31, 2025
Renaissance Technologies LLC
2.50M
2.53%
+13.30K
+0.53%
Mar 31, 2025
Wellington Management Company, LLP
2.10M
2.12%
+640.56K
+43.95%
Mar 31, 2025
JP Morgan Asset Management
2.03M
2.05%
+985.43K
+94.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.97M
1.99%
+94.69K
+5.05%
Mar 31, 2025
Bellevue Asset Management AG
1.82M
1.84%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
1.49M
1.5%
+627.00K
+72.74%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Tema Neuroscience and Mental Health ETF
4.95%
Simplify Health Care ETF
4.48%
AdvisorShares Psychedelics ETF
4.41%
iShares Neuroscience and Healthcare ETF
4.39%
First Trust NYSE Arca Biotechnology Index Fund
4.35%
VanEck Biotech ETF
2.85%
Invesco Biotechnology & Genome ETF
2.72%
Goldman Sachs Future Health Care Equity ETF
2.52%
SPDR S&P Biotech ETF
2.46%
Alger Russell Innovation ETF
2.21%
查看更多
Tema Neuroscience and Mental Health ETF
佔比4.95%
Simplify Health Care ETF
佔比4.48%
AdvisorShares Psychedelics ETF
佔比4.41%
iShares Neuroscience and Healthcare ETF
佔比4.39%
First Trust NYSE Arca Biotechnology Index Fund
佔比4.35%
VanEck Biotech ETF
佔比2.85%
Invesco Biotechnology & Genome ETF
佔比2.72%
Goldman Sachs Future Health Care Equity ETF
佔比2.52%
SPDR S&P Biotech ETF
佔比2.46%
Alger Russell Innovation ETF
佔比2.21%
分紅派息
近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
KeyAI